Ketoconazole, an imidazole absorbed when administered orally, inhibits the growth of Coccidioides immitis (4, 6) , Candida albicans (4, 12) , and Candida parapsilosis (4) at concentrations of <1 ,ug/ml and Aspergillus spp. and Torulopsis glabrata at concentrations of 2 to 10 ,ug/ml or more. Fungal infections due to Candida spp., particularly C. albicans, and Aspergillus sp. are a common cause of mortality and morbidity in patients with acute leukemia and other advanced malignancies (3) . Because these patients are at high risk of fungal infection, we conducted a study to evaluate the potential of ketoconazole as a prophylactic and therapeutic antifungal agent. Studies of plasma concentrations and urinary elimination were performed to guide dosage and schedule of administration in these patients.
MATERIALS AND METHODS
The plasma concentrations of ketoconazole were measured in 26 patients with acute leukemia and 1 patient with thyroid carcinoma. Nineteen males and eight females, ranging in age from 18 to 76 years (median, 45 years), participated in the study. All patients had been assigned to receive ketoconazole as therapy or prophylaxis of fungal infection and were requested to participate in the pharmacological study. Informed consent was obtained from all patients according to institutional policy. Renal and hepatic func-oxo.
tions were assessed before treatment and at least weekly thereafter by the measurement of serum glutamic oxaloacetic transaminase and alkaline phosphatase. All parameters were normal throughout the study in 16 patients. Eleven patients had slight elevations of alkaline phosphatase or serum glutamic oxalacetic transaminase initially; however, as their plasma ketoconazole concentrations did not differ significantly from those of other patients, all results were combined in the analysis.
Ketoconazole was administered orally at least 1 h before or after food ingestion. Antacids were avoided except when considered mandatory for patient management; they were administered at least 2 h from the time of ketoconazole administration.
Twenty-three patients were given 200 mg of ketoconazole every 6 h for 4 to 35 days. Blood samples were drawn before and 2, 4, and 6 h after the administration of the drug. Serial studies were performed on six patients on days 1, 8, and 15 of drug administration. Four patients were studied on day 1 only, and eight patients were studied on day 3 or 4 only. Five patients were studied up to 18 h after drug administration after 7 days of treatment.
Four patients were given 200 mg of ketoconazole every 12 h for 8 (13) with an open single-compartment model.
RESULTS
After the initial dose of ketoconazole, the mean peak plasma concentration in six patients on the every-6-h schedule was 1.6 ± 0.4 ,ug/ml 2 h after drug administration (Table 1) . After 6 h, the mean plasma concentration was 0.6 ± 0.1 ,g/ml. The mean peak concentration on day 8 rose to 3.1 ± 0.6 ,ug/ml, significantly higher than that on day 1 (P < 0.05). The mean concentration at 2 h on day 15 was 3.6 ± 0.4 ,ug/ml (P > 0.05). The mean concentrations before the administration of the drug on days 8 and 15 were 2.6 and 2.4 ,ug/ml, respectively. The data from four patients studied on day 3 or 4 only (every-6-h schedule) were similar to those from patients studied sequentially on days 8 and 15. For patients on the every-12-h schedule, the mean peak plasma concentration of ketoconazole was 1.8 ± 0.6 ,ug/ml on day 1, 2.7 ± 1.1 ,ug/ ml on day 8, and 3.6 ± 2.1 ,ug/ml on day 15. These values are not significantly different at the P = 0.05 level because of variability. In two patients, concentrations were <1 ,ug/ml before drug administration on day 15. The highest plasma concentration of ketoconazole measured on day 1 in all patients occurred 2 h after administration in 10 patients and 4 h after administration in the other 4 patients. The highest concentration measured at 2 h was 3.5 Fg/ml, and the lowest was 0.2 ,ug/ml.
Samples were drawn for 18 h after the last dose from five patients who had received ketoconazole every 6 h for 7 days (Fig. 1) . The peak serum concentration was 3.8 ± 0.8 ,ug/ml at 2 h; the mean concentration at 18 h was 0.2 ± 0.1 ,ug/ ml. The mean plasma tj,2 in this group was 3.5 1.3 h.
The AUC and the plasma tj,2 of ketoconazole in sequentially studied patients are given in Table 2 . The AUC values increased for patients on the every-6-h schedule from 12.0 jag'h/ml on day 1 to 27.0 ug-h/ml on day 8. No difference was noted between values on days 8 and 15. The tj,2was 5.1 ± 1.5 h on day 1 and 3.9 ± 0.8 h on day 15. The change in AUC was not as great for patients on the every-12-h schedule from days 1 to 15. The mean tj,2 was 3.0 h on days 1 and 15 and 2.4 h on day 8. The mean tj,2 for all patients studied on day 1 was 3.7 ± 0.6 h.
In 7 of 12 patients from whom urine samples were collected, no drug was detectable in urine for 6 h after the administration of the initial dose of ketoconazole. In five other patients, a mean amount of 0.5 mg was excreted over the 6-h collection period (0.02 to 1.38 mg).
No patient on either schedule developed severe toxicity attributable to ketoconazole. The The mean peak plasma concentration of ketoand 6 of 23 conazole on day 1 for the patients on the every-). The drug 6-h schedule was 1.6 ,ug/ml, lower than that one patient reported by Brass et al. for 10 patients given side effects single doses of ketoconazole (2.75 jig/ml) (5) .
ts) and ano-The difference could be related to the effect of in renal or chemotherapy on the absorption of the drug or the admin-to the underlying malignancies in our patients. The mean peak concentration on day 8 was 3.1 ,ug/ml, similar to that reported for miconazole 20 min after the infusion of 9 mg/kg (3.1 ,ug/ml) (14) . to ampho-Lewi et al. have reported a triphasic drug disaprtain fungal pearance curve for miconazole, with a second t1/2 ty with mi-of 2.1 h, somewhat shorter than that reported hyperlipid-here for ketoconazole (11) . We were unable to and cardiac detect a prolonged terminal phase in the eliminain part to tion of ketoconazole because of the design of the n the drug study and the limitation on the quantitation of g imidazole, plasma concentrations of <0.1 ,ug/ml with the as active as techniques employed. ngal species Plasma concentrations of ketoconazole were D patients in usually less than 1 jig/ml in patients on the every-12-h schedule before the administration of Ltions were the drug on days 8 and 15. Concentrations t1 dose. The remained consistently above 1 ,ug/ml in patients ample times on the every-6-h schedule. Since in vitro susceptn the every-tibility to ketoconazole varies among fungal speig since the cies and because the presence of neutrophils i; thus, drug may be of particular importance for the effecpatients on tiveness of this drug (7), the every-6-h schedule Lule, equilib-may be preferable, especially for patients who have been have prolonged periods of profound neutropethe plasma nia.
were simiThe progressive rise in the calculated AUC in No severe or unexpected toxicities were recognized in the patients in this study. The most common toxic effects were nausea and anorexia, more prevalent in patients on the every-6-h schedule. No evidence of hepatic or renal toxicity was noted. Two patients experienced drowsiness, which resolved when the drug was discontinued.
Conclusions. Ketoconazole (200 mg orally every 6 h) was absorbed to potentially therapeutic concentrations in a group of patients with advanced malignancies, most of whom were being actively treated for acute leukemia. Plasma concentrations of ketoconazole were lower and more variable when the drug was given every 12 h. The t1j2 ranged from 1.3 to 11.6 h, suggesting that many patients require frequent dose administration to maintain therapeutic concentrations of ketoconazole. The drug appears to be highly bound in plasma and widely distributed throughout the body.
Renal excretion accounts for a very small proportion of drug elimination, suggesting the importance of other routes of excretion or metabolism.
Ketoconazole was well tolerated by patients on both administration schedules, and no significant toxicity was encountered in any patient studied. Nausea and anorexia were the most common side effects, particularly in patients on the every-6-h schedule.
Studies to evaluate the prophylactic and therapeutic potential of this drug in patients with advanced malignancies appear to be warranted.
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